In this regard, we showed that Ptpn22−/− T cells were superior to control cells in responding to both high- and low-affinity TSA and in mediating tumor rejection in vivo, suggesting that targeting PTPN22 may be a viable approach in T cell immunotherapies. This evidence concerns the gene PTPN22 and neoplasm.